Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: What is the potential for prevention?

Cancer Causes and Control

Volumn 25, Issue 2, 2014, Pages 179-189

  Kjær, Susanne K ^a,b   Munk, Christian ^a   Junge, Jette ^c   Iftner, Thomas ^d  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Genotyping; HPV; Population based; Prevalence

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; FEMALE; GENOTYPING TECHNIQUE; HEALTH IMPACT ASSESSMENT; HIGH GRADE CERVICAL LESION; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPECIES DIFFERENCE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VERY ELDERLY; VIRUS IDENTIFICATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CERVIX UTERI; DENMARK; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84893644722     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0320-z     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917. doi: 10.1002/ijc.25516
2. Muñoz N, Castellsagué X, de Gonzáles AB, Gissman L (2006) Chapter 1. HPV in the etiology of human cancer. Vaccine 24(Suppl 3):1-10
3. NORDCAN (http://www.ancr.nu/default-old.asp) updated Oct. 2009
4. Noehr B, Jensen A, Frederiksen K, Tabor A, Kjaer SK (2009) Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: A population-based study of singleton deliveries during a 9-year period. Am J Obstet Gynecol 201(1):33.e1-6. doi: 10.1016/j.ajog.2009.02. 004
5. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romonowski B, Roteli-Martins CM et al (2006) Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367:1247-1255
6. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G et al (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2(10):868-878. doi: 10.1158/1940-6207.CAPR-09-0031
7. Lehtinen M, Dillner J (2013) Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 10(7):400-410. doi: 10.1038/nrclinonc. 2013.84
8. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928-1943
9. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) virus-like particle vaccine against high-grade vulvar and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 369(9574):1693-1702
10. Nielsen A, Kjaer SK, Munk C, Iftner T (2008) Type-specific HPV infection and multiple HPV types: Prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 35(3):276-282
11. Kjær SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T (2008) Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 123(8):1864-1870
12. Nielsen A, Iftner T, Nørgaard M, Munk C, Junge J, Kjaer SK (2012) The importance of low-risk HPV infection for the risk of abnormal cervical cytology/histology in more than 40 000 Danish women. Sex Transm Infect 88(8):627-632. doi: 10.1136/sextrans-2011-050307
13. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al (2009) The impact of quadrivalent hpv (type 6/11/16/18) L1 VLP vaccine on infection and disease due to Oncogenic non-vaccine HPV types in generally HPV naive women aged 16-26. J Infect Dis 199(7):926-935
14. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G (2009) The impact of quadrivalent HPV (types 6/11/16/18) L1 vlp vaccine on infection and disease due to oncogenic non-vaccine hpv types in sexually active women aged 16-26. J Infect Dis 199(7):936-944
15. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M (2012) Crossprotective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infect Dis 12(10):781-789
16. Munk C, Kjaer SK, Poll P, Bock JE (1998) Cervical cancer screening: Knowledge of own screening status among women aged 20-29 years. Acta Obstet Gynecol Scand 77(9):917-922
17. Pedersen CB (2011) The Danish civil registration system. Scand J Public Health 39(Suppl 7):22-25
18. Bjerregaard B, Larsen OB (2011) The Danish pathology register. Scand J Public Health 39(Suppl 7):72-74
19. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S (2010) Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202(12):1789-1799. doi: 10.1086/657321
20. Jensen KE, Munk C, Sparen P, Tryggvadottir L, Liaw KL, Dasbach E, Nygård M, Kjaer SK (2011) Women's sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand 90(5):459-467. doi: 10.1111/j.1600-0412.2010.01066.x
21. Nielsen A, Kjaer SK, Munk C, Osler M, Iftner T (2010) Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol 82(4):616-623. doi: 10.1002/jmv.21750
22. Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O'Reilly S, Kiviat NB, Koutsky LA (2011) Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20(4):699-707
23. Passmore JA, Morroni C, Shapiro S, Williamson AL, Hoffman M (2007) Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm (Lond) 4:8
24. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J (2009) Triage of women with equivocal or low-grade cervical cytology results: A meta-analysis of the HPV test positivity rate. J Cell Mol Med 13(4):648-659. doi: 10.1111/j.1582-4934.2008.00631.x
25. Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C (2009) Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 18(1):321-330. doi: 10.1158/1055-9965.EPI-08-0510
26. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, Kitchener HC, ARTISTIC Study Group (2008) Prevalence of type-specific HPV infection by age and grade of cervical cytology: Data from the ARTISTIC trial. Br J Cancer 98(10):1704-1709. doi: 10.1038/sj.bjc.6604324
27. Kjær SK, Frederiksen K, Munk C, Iftner T (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102(19):1478-1488. doi: 10.1093/jnci/djq356
28. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 337:a1754
29. Kjaer S, Høgdall E, Frederiksen K, Munk C, van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T (2006) The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66(21):10630-10636
30. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst 98(5):303-315
31. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J et al (2005) Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191:1796-1807
32. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE (2010) Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 19:1675-1681
33. Castle PE, Shaber R, Lamere B, Kinney W, Fetterman B, Poitras N et al (2011) Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev 20:946-953
34. Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, Kjær SK (2012) HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol 124(2):281-285. doi: 10.1016/j.ygyno. 2011.10.020
35. Blomberg M, Dehlendorff C, Munk C, Kjaer SK (2013) Strongly decreased risk of genital warts after vaccination against human papillomavirus: Nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 57(7):929-934. doi: 10.1093/cid/cit436